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Strengths and limitations of this study
 ► We analysed the content of UK websites about cervi-
cal cancer screening using an established checklist 
of information items, and identified additional infor-
mation that was mentioned commonly.
 ► We systematically examined whether cancer 
screening websites present probabilistic information 
in formats recommended in the risk communication 
literature.
 ► We identified websites by applying the most com-
mon Google search terms used in the UK to find in-
formation on cervical screening, and examined the 
majority of links that users will realistically access.
 ► All the information items we assessed may not be 
relevant for screening decisions, whereas we may 
have omitted some information that can be relevant 
(eg, about the human papillomavirus).
 ► We did not examine whether websites mentioned 
the uncertainty associated with estimates of ben-
efits and risks, although such information can be 
important for informed decision-making.
AbStrACt
Objectives To investigate whether UK websites about 
cervical cancer screening targeted to the public include (1) 
information about benefits and risks of screening, possible 
screening results and cervical cancer statistics, (2) 
quantitative presentation formats recommended in the risk 
communication literature and (3) appeals for participation 
and/or informed decision-making.
Design Cross-sectional analysis of websites using a 
comprehensive checklist of information items on screening 
benefits, risks, possible results and cervical cancer 
statistics.
Outcome measures We recorded the number of websites 
that contained each of the information items, and the 
presentation format used for probabilistic information (no 
quantification provided, verbal quantifiers only, different 
types of numerical formats and/or graphs). We also 
recorded the number of websites containing appeals for 
participation and/or informed decision-making.
Setting Websites were identified through the most 
common Google search terms used in the UK to 
find information on cervical screening, according to 
GoogleTrends and a commercial internet-monitoring 
programme. Two additional websites were identified by the 
authors as relevant.
results After applying exclusion criteria, 14 websites 
were evaluated, including websites of public and private 
health service providers, charities, a medical society and 
a pharmacy. The websites mentioned different benefits, 
risks of screening and possible results. However, specific 
content varied between websites. Probabilistic information 
was often presented using non-recommended formats, 
including relative risk reductions to express screening 
benefits, and verbal quantifiers without numbers to 
express risks. Appeals for participation were present in 
most websites, with almost half also mentioning informed 
decision-making.
Conclusions UK websites about cervical cancer screening 
were generally balanced. However, benefits and risks were 
presented using different formats, potentially hindering 
comparisons. Additionally, recommendations from the 
literature to facilitate understanding of quantitative 
information and facilitate informed decisions were often 
not followed. Designing websites that adhere to existing 
recommendations may support informed screening uptake.
IntrODuCtIOn
Cervical cancer is highly preventable. It is 
caused in most cases by an infection with the 
human papillomavirus (HPV), which may 
lead to abnormal changes in cervical cells.1 2 
Such abnormalities can be detected through 
screening and treated before they become 
cancerous.3 Indeed, cervical screening signifi-
cantly reduces both cervical cancer incidence 
and cancer-specific mortality.3–7 In the UK, 
age-standardised incidence was 11.8 in 100 
000 in 2014, and age-standardised mortality 
was 3.3 in 100 000.8 In England alone, esti-
mates suggest that there would be 1827 addi-
tional cervical cancer deaths per year without 
screening.7
However, cervical screening is associated 
with potential risks, including the detection 
of indolent abnormal cells that would have 
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Table 1 Evidence-based recommendations from the risk communication literature to promote understanding of probabilistic 
information
Recommendation Rationale Key references
Avoid the use of verbal quantifiers 
without numbers (eg, women who have 
abnormal cells removed are slightly more 
likely to have their baby early).
Interpretations of verbal quantifiers 
vary across individuals and often 
differ from interpretations intended by 
communicators. Verbal quantifiers can 
lead to overestimations of risks.
Budescu et al77; Knapp et al55 56; Peters 
et al57; Visschers et al53; Young and 
Oppenheimer58; Zipkin et al38
Avoid numerical ‘1-in-X’ formats to 
present the chance of an outcome (eg, 1 
in 12 women will have an abnormal test 
result).
People tend to perceive the same 
probabilities as higher and more worrying 
when presented using ‘1-in-X’ ratios, as 
compared with numerically equivalent 
‘N-in-X*N’ ratios (eg, 10 in 120 women 
will have an abnormal test result) or 
percentages (eg, 8% of women will have 
an abnormal test result).
  Pighin et al78 79; Sirota et al54 80 81; 
Trevena et al48; Zikmund-Fisher39
Avoid presenting estimates of risk 
reduction in relative terms (eg, screening 
cuts the risk of getting cervical cancer by 
75%).
Relative risk differences can obscure the 
true magnitude of benefit or harm, as 
compared with absolute risk differences 
(eg, screening reduces the risk of getting 
cervical cancer from 20 in 1000 to 5 in 
1000).
Akl et al82; Covey83; Fagerlin et al22; 
Gigerenzer et al21 84; Trevena et al48; 
Zipkin et al38
Add simple graphical displays of 
numerical information (eg, icon arrays, 
where icons of different colours represent 
those affected and not affected by the 
risk).
Well-designed, simple graphs help to 
overcome difficulties in understanding 
numerical information and are often 
perceived as more appealing and easier 
to understand.
Galesic et al85; Garcia-Retamero and 
Cokely40; Gigerenzer and Edwards84; 
Okan et al86; Paling87; Schapira et al88
cleared up on their own (ie, overdiagnosis), potentially 
leading to unnecessary treatment.9 10 A recent meta-anal-
ysis indicates that about half of untreated moderately 
abnormal cells regress within 2 years,9 suggesting that 
overtreatment is relatively common. The removal of large 
amounts of tissue during treatment can also increase the 
risk of preterm birth in future pregnancies.11–13 However, 
experts and policy-makers generally agree that benefits 
of cervical screening outweigh potential risks.5 14 15 In the 
UK, the National Health Service (NHS) offers screening 
to all women aged 25–64. It has been emphasised that 
screening invitees need information about both benefits 
and risks to make informed decisions about participa-
tion.14 16 17
Organised screening programmes often use written 
outreach materials. In the UK, eligible women receive an 
invitation letter with an information leaflet that mentions 
websites about cervical screening. Hence, it is important 
to examine whether widely accessed websites effectively 
support decisions about screening participation. Both 
European and UK guidelines have emphasised that 
cancer screening communications should be comprehen-
sive in content, and should provide balanced discussions 
of benefits and risks to screening.17–20 Such guidelines 
have also highlighted that screening communications 
should be comprehensible, and avoid quantitative presen-
tations that are hard to understand.17–19 Communications 
that are not well understood can cause undue concern, 
reduce recipients’ self-efficacy beliefs about their capacity 
to participate in screening and undermine informed 
decision-making.21 22
Quantitative information in screening communica-
tions, however, can be challenging even for educated 
audiences.21 23 Such information can be presented using a 
range of formats, including verbal quantifiers (eg, ‘low’ or 
‘moderate’ risk), various numerical formats and graphical 
displays (eg, icon arrays). Research in risk communica-
tion has shown that quantitative presentation formats vary 
considerably in their effectiveness to promote accurate 
understanding. Some formats are known to be relatively 
ineffective, while others still lack conclusive evidence.24 
Table 1 provides an overview of quantitative formats, asso-
ciated evidence-based recommendations and supporting 
references. Key recommendations relevant to screening 
communications include avoiding the use of verbal 
quantifiers without accompanying numbers, numerical 
‘1-in-X’ formats and presentations of risk reductions in 
relative terms. Another recommendation is to add simple 
graphical displays to numerical information.
Existing guidelines also state that screening communi-
cations should not persuade people to attend or present 
screening as necessary or important, without acknowl-
edging that not participating is a reasonable choice.17–20 
Recent guidance from the UK National Screening 
Committee17 notes that ‘information should make it clear 
that it is a personal choice to accept or decline screening 
and both choices will be fully supported’ (p6). This 
approach to screening communications seeks to respect 
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personal autonomy and ensure that decisions are in line 
with invitees’ personal values and circumstances—espe-
cially since healthy individuals can be adversely affected 
by screening.25 26 Besides undermining the principle of 
autonomy, persuasive messages may have unintended 
negative effects, such as eliciting guilt and anxiety among 
invitees who decline the offer, anger among those who 
participate and are harmed as a result, and potential 
mistrust in communicators over time.20 26 27
We investigated whether UK websites about cervical 
screening adhere to existing guidelines and policy recom-
mendations concerning information content and appeals 
for informed decision-making (vs for participation), 
as well as to recommendations from the risk communi-
cation literature concerning quantitative presentation 
formats. Previous website analyses have primarily focused 
on breast cancer screening, and have generally assessed 
only website content25 28 or a specific aspect of presenta-
tion format (eg, consistency in the presentation of statis-
tics on overdiagnosis29).
We used an established checklist of information items 
about cervical screening,30 building on earlier evaluations 
of breast cancer screening communications.25 31 32 We 
assessed quantitative presentation formats considering 
the recommendations listed in table 1. Additionally, we 
examined the type of appeals included in websites. In 
sum, our research questions were:
1. Do UK websites about cervical screening contain (a) 
key information about screening benefits, risks, possi-
ble results, and (b) cervical cancer statistics?
2. Do UK websites about cervical screening present prob-
abilistic information using recommended formats?
3. Do UK websites about cervical screening contain ap-
peals for participation and/or informed decision 
making?
MethODS
Search strategy
We used GoogleTrends to identify the most common 
Google search terms used in the UK to find informa-
tion on cervical screening. We identified search terms 
related to ‘cervical screening’ in the 12 months prior to 
March 2017. We used ‘cervical screening’ based on the 
invitations from the UK’s NHS. Related search terms 
included ‘cervical cancer screening,’ ‘cervical smear’ and 
‘smear test’. To determine which of these terms was more 
common, we used Wordtracker (https:// app. wordtracker. 
com/), a commercial programme that estimates the rela-
tive frequency of Google search terms in a given period of 
time (see Ref. 33 for a similar procedure). The two most 
commonly used terms in the UK in the year before March 
2017 were ‘smear test’ and ‘cervical screening’.
Website selection
On 9 March 2017, we performed the Google search 
‘smear test’ OR ‘cervical screening’ using the private 
Firefox browsing mode to prevent previously visited pages 
and cookies from influencing search results. Following 
Ghanouni et al,29 we examined the first five pages of 
results using the default of 10 results per page, (i.e., 50 
links). This includes the vast majority of websites that 
users will access (see also Ref. 34). The full list of links is 
available at the Open Science Framework (https:// doi. 
org/ 10. 17605/ OSF. IO/ 73GFN).
We excluded links that (1) targeted healthcare profes-
sionals and academics rather than laypeople (eg, tech-
nical reports, research articles), (2) reflected online 
media articles or press releases, (3) presented interna-
tional information not applicable to the UK (eg, Wikipe-
dia’s overview of screening recommendations in different 
countries) and (4) were locally or regionally oriented. 
The latter links typically focused on basic practical aspects 
(eg, who is eligible for screening and logistics of making 
appointments for specific general practice surgeries), and 
often provided links for further information to national 
websites included in our analyses. We also excluded links 
that (5) were duplicate, (6) contained no or little informa-
tion about cervical screening (<150 words) and (7) had 
no written materials (eg, YouTube video). Additionally, 
we included two websites identified through our knowl-
edge of resources on cervical screening (Patient and 
Women’s Health Concern). Although these websites did 
not appear in the Google search, they represent trusted 
UK resources that some women may access directly to 
learn about cervical screening. Figure 1 summarises the 
website selection process.
For the websites identified through Google, we coded 
the link listed in the search results. For the two additional 
websites, we coded the main link providing informa-
tion about cervical screening. In all cases, we also coded 
sections on cervical screening within each website that 
could be directly accessed from the initial link, as well 
as other written materials directly accessible, including 
electronic leaflets, fact sheets and slideshows, which were 
all considered as part of the same resource in analyses. 
Websites were accessed between 20 March 2017 and 28 
April 2017, except one website (BootsWebMD), which was 
accessed at a later date due to an oversight in the initial 
website selection. The date of accessing each website, 
corresponding links and estimated number of visits 
appears in supplementary materials (online supplemen-
tary table S1). Copies of PDF files reflecting the content 
of all websites at the time of access are available at the 
Open Science Framework.
Coding of websites
To code website content, we adapted a checklist of informa-
tion items that was developed to analyse invitations for cervical 
screening.30 Following European and UK guidelines,18 19 the 
checklist included items about screening benefits, risks and 
possible results (eg, the possibility of an abnormal or an inad-
equate result). Following Kolthoff et al,30 the item on overdi-
agnosis/overtreatment included any reference to screening 
possibly detecting abnormal cells that may clear up on their 
own and/or leading to unnecessary treatment, regardless of 
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Figure 2 Results of analysis of content and quantitative presentation formats for information about (A) cervical screening 
benefits, (B) risks, (C) possible results and (D) cervical cancer statistics. A total of 14 websites were analysed. Items marked with 
an asterisk were added by the authors to the checklist by Kolthoff et al.30 Details concerning instances in which multiple formats 
were used for a given information item appear in supplementary materials (online supplementary table S3).
Figure 1 Flow chart representing the website selection process.
whether the treatment type was mentioned (see also Refs).35 36 
The checklist also included items about cervical cancer statis-
tics (eg, lifetime risk of developing cervical cancer), which 
may be relevant for screening decisions.25 31 32 After initial 
inspection of the websites, we added five items to the check-
list to reflect commonly presented information that may 
also influence screening decisions (figure 2). Examples of 
all information items appear in supplementary materials 
(online supplementary table S2).
To assess quantitative presentation formats, we coded 
whether probabilistic information was presented using: 
no quantifiers, verbal quantifiers only, numerical quan-
tifiers (1-in-X vs other numerical format) and/or graphs. 
We also coded whether any information about risk reduc-
tion was presented in relative terms. Multiple formats (eg, 
graphs accompanied by numbers) were present in some 
communication materials (online supplementary table 
S3, supplementary materials).
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Finally, we coded appeals for informed decision-making 
(eg, ‘deciding whether to have screening or not is your 
choice’) and appeals for participation. Following Kolthoff 
et al,30 the latter included direct encouragement for 
participation (eg, ‘a smear test—have it’) and statements 
presenting screening as necessary (eg, ‘it’s essential 
for women to have regular cervical screening tests’) or 
important (eg, ‘it is important to go for screening every 
time you are invited’).
The first author (YO) read through all selected mate-
rials and applied the coding scheme. Three websites 
(>20%) were coded by another author (SGS). Cohen’s 
kappa was moderate to high on all codes except ‘type of 
appeal’ (0.18). Discrepancies for this code were caused 
by appeals for participation that were not prominent. 
These discrepancies were resolved through discussion, 
resulting in consensus. The average Cohen’s kappa was 
0.86 (range: 0.65–1).
Patient and public involvement
Patients and/or public were not involved in the design 
or conduct of the study, which did not involve human 
participants.
reSultS
Website selection
As described above, we identified 50 links through our 
Google search. After exclusions, 12 websites remained, 
including 4 websites from public health service providers 
in the UK’s four countries (NHS Choices England, NHS 
Inform Scotland, Public Health Agency Northern Ireland, 
Public Health Wales), 1 private health service provider 
(Bupa UK), 3 cancer charities (Cancer Research UK, 
Jo’s Cervical Cancer Trust, MacMillan Cancer Support), 
2 additional charities (LGBT Foundation, Marie Stopes 
UK), 1 medical society (British Society for Colposcopy 
and Cervical Pathology) and 1 pharmacy (Boots WebMD). 
All websites from public health service providers included 
links to official invitation leaflets, which were coded with 
the corresponding website, as described above. As noted 
earlier, two additional websites (Patient and Women’s 
Health Concern) were identified by the authors. Below, 
we present summary statistics across websites. Results for 
individual websites appear in supplementary materials 
(online supplementary table S3).
Do uK websites about cervical screening contain (a) key 
information about screening benefits, risks, possible results 
and (b) cervical cancer statistics?
We report on four main findings regarding website 
content. First, screening benefits were mentioned 
frequently, although the focus was primarily on risk 
reduction of developing cervical cancer (figure 2A). Esti-
mates of risk reduction typically varied between 70% and 
80%. Based on Sasieni et al,37 two websites provided an 
estimated range of 60%–80%, and another provided an 
estimate of 90% for the reduction in the risk of advanced 
cancer specifically. No websites explicitly mentioned risk 
reductions of death from cervical cancer or total mortality. 
Instead, benefits were often expressed in terms of the 
number of lives saved yearly (eg, ‘cervical screening saves 
5000 lives a year in the UK’; n=10 websites), or in some 
cases referring to the fall in cervical cancer cases since the 
national screening programme was initiated (eg, ‘since 
the screening programme was introduced in the 1980s, 
the number of cervical cancer cases has decreased by 
about 7% each year’; n=6).
Second, screening risks were also mentioned relatively 
frequently (figure 2B), but the specific risks and their 
descriptions varied across websites. The most commonly 
mentioned risks were overdiagnosis and overtreatment 
(n=12), pain/discomfort related to the test (n=12) and 
the possibility of false negatives (n=10). Descriptions of 
overdiagnosis, however, generally focused on cell changes 
often clearing up and not progressing into cancer (eg, 
‘in most cases, the abnormal cells will disappear on their 
own’). The risk of unnecessary additional tests or treat-
ment was only mentioned explicitly in seven cases, often 
in connection to justifications for current screening age 
ranges (eg, ‘changes in a young woman’s cervix are quite 
normal. In this situation, screening may lead to unnec-
essary treatment’). Most websites described the test as 
uncomfortable but not painful (eg, ‘having the speculum 
put in may be a little uncomfortable, but it shouldn’t 
hurt’), though one website did state that the test was 
potentially painful. Risks related to treatment were only 
mentioned in half of the websites, all of which referred to 
the possibility of premature birth. Two of them also noted 
the risk of stenosis (ie, the cervix becoming tightly closed 
after treatment).
Third, possible screening results were mentioned in 
most websites (figure 2C). Estimates of the likelihood 
of inadequate results varied between 1.7% and 3% and 
estimates of the likelihood of abnormal results ranged 
between 5% and 10%. Additionally, the possibility of 
cancer diagnosis was mentioned in over half of the 
websites (n=8) and was often reported as occurring in less 
than 1 in 1000 cases.
Finally, cervical cancer statistics such as lifetime risk 
of developing or dying from cervical cancer were not 
discussed, although some websites did provide details 
on cervical cancer incidence and mortality (figure 2D). 
Specific estimates of incidence varied across websites, and 
included yearly, daily, national and regional estimates 
(eg, ‘each year in Northern Ireland, about 103 women 
are diagnosed with cervical cancer’).
Do uK websites about cervical screening present probabilistic 
information using recommended formats?
Information was often not presented in recommended 
formats. First, the recommendation to avoid the use 
of verbal quantifiers without numbers38 was often not 
followed for information about risks (figure 2B). Risks 
related to treatment were quantified only verbally, gener-
ally using varying verbal quantifiers. For example, one 
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website stated that ‘women are slightly more likely to have 
their baby 1 to 2 months early’, and another stated that 
‘women may have a higher risk of preterm delivery’. Other 
risks were also either only quantified verbally or not quan-
tified at all, with the exception of overdiagnosis/over-
treatment (n=3) and false-negative results (n=2).
Second, the recommendation to avoid ‘1-in-X’ numer-
ical formats39 was often violated for information about 
screening results. This was the most popular format for 
conveying the likelihood of abnormal results (figure 2C). 
Third, the recommendation to avoid presentations of 
relative risk reduction21 was violated in most cases in which 
an estimate of risk reduction was provided (figure 2A). 
Finally, the recommendation to add simple graphical 
displays40 was often not met. Only two websites contained 
graphs, each depicting the likelihood of abnormal results.
Do uK websites about cervical screening contain appeals for 
participation and/or informed decision-making?
Appeals for participation were present in most websites 
(n=12). Specifically, appeals for participation without 
mention of informed decision-making occurred in half of 
the websites (n=7). Several websites combined appeals for 
participation and informed decision-making (n=5) (eg, 
‘don’t ignore your smear test, it could save your life’ and 
‘taking part in cervical screening is your choice’). One 
website (NHS Choices England) referred to informed 
decision-making only (‘deciding whether or not to have a 
cervical screening test is your choice’). The websites of the 
three remaining public health service providers included 
either both appeals for participation and informed deci-
sion-making (NHS Inform Scotland and Public Health 
Wales) or only appeals for participation (Public Health 
Agency Northern Ireland).
DISCuSSIOn
We investigated whether UK websites about cervical 
screening adhered to existing recommendations about 
content, quantitative presentation formats and type of 
appeals. We found that websites often followed recom-
mendations from European and UK guidelines to 
include information about both benefits and risks of 
screening.17–19 However, specific content varied across 
websites. For example, only half of the websites explic-
itly referred to risks related to the treatment of abnormal 
cells. Additionally, probabilistic information was often 
presented in formats not recommended in the risk 
communication literature, including relative risk reduc-
tions to express screening benefits, and verbal quanti-
fiers without numbers to express risks. Moreover, several 
websites encouraged screening participation without 
referring to informed decision-making, contrasting with 
current UK policy.14 41
Our finding that websites often included informa-
tion about both benefits and risks of cervical screening 
contrasts with previous reports that breast screening 
websites lacked information about risks such as 
overdiagnosis.25 28 Recent emphasis in the UK on facili-
tating informed screening decisions14 41 may have led to 
more comprehensive and balanced websites in recent 
years (see also Ref. 29). The presence of information 
about both screening benefits and risks is aligned with 
women’s preferences, who often want to receive informa-
tion on both aspects before their test.42 However, we also 
found that websites generally presented benefits and risks 
using different formats (numbers vs verbal quantifiers, 
respectively), potentially hindering benefit–risk compari-
sons. Additionally, our finding that specific content varied 
across websites suggests that women accessing different 
resources may come to different conclusions.
Our results also suggest that existing descriptions of 
benefits and risks may not always support understanding. 
For example, the concepts of overdiagnosis and over-
treatment are often unfamiliar and counterintuitive to 
people,43–45 highlighting the need to provide explana-
tions that are accessible and transparent. Many websites 
did explain that cell changes often clear up on their 
own. This may help women to understand that cervical 
screening can lead to overdiagnosis of indolent abnor-
malities (potentially causing unnecessary anxiety or 
worries36), but not necessarily that it may result in unnec-
essary treatment. Moreover, the websites that explicitly 
mentioned overtreatment often did so in relation to 
women below the recommended screening age. Hence, 
those within the recommended age may incorrectly infer 
that such risk does not apply to them. We also found that 
many websites emphasised that screening ‘saves lives’. 
It has been argued that such claims are misleading, 
and that communications should report reductions in 
cancer-specific mortality, overall mortality, as well as 
overall cancer deaths.46 Although there is evidence that 
cervical screening reduces cancer-specific mortality,3–7 
determining its impact on overall mortality requires large 
trials with sufficient power to detect differences.47
Our finding that probabilistic information was often 
presented in non-recommended formats is concerning 
as this may cause misperceptions, even among educated 
audiences. The use of relative risk reductions to express 
screening benefits can hinder understanding and increase 
risk perceptions, relative to presentations of absolute risk 
reduction.38 48 Although information about baseline risk 
(ie, the absolute risk without screening) could reduce 
the biassing effect of relative risks49 (but see Ref. 50), 
such beneficial impact may be limited to baseline risks 
presented in frequency formats (vs probabilities)51 52 
and to more (vs less) numerate recipients.52 Moreover, 
we did not find such information in any of the websites. 
It has been argued, however, that presentations of rela-
tive risks may be considered for low-probability risks with 
high impact (eg, an earthquake), to prevent people from 
neglecting such risks altogether.24 53
Additionally, our results suggest that women may over-
estimate the likelihood of abnormal screening results due 
to the use of ‘1-in-X’ formats (eg, ‘1 in 12 women will 
have an abnormal test result’).54 Similarly, screening risks 
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expressed using verbal quantifiers without numbers may 
be overestimated.55–58 The absence of numerical infor-
mation can also lead people to perceive communications 
as less credible and trustworthy.53 59 60 Although some 
risks are hard to quantify (eg, psychological distress), 
estimates are available for risks such as preterm birth or 
overtreatment, from observational studies and meta-anal-
yses.9 11 13 The best available evidence could be presented 
in transparent fact boxes—a tabular format that facilitates 
comparisons of outcomes in groups of screened versus 
unscreened individuals.61 Fact boxes can also include 
simple graphs such as icon arrays to allow visual compar-
ison of quantities,62 which could be especially beneficial 
for people with low numeracy. Yet, graphs were seldom 
used in cervical screening websites.
Finally, our finding that some websites encouraged 
screening without mentioning informed decision-making 
contrasts with current UK policy, which emphasises that 
communications can recommend screening, but should 
acknowledge that not accepting the offer is a reasonable 
choice.14 20 41 Although there is largely agreement that 
benefits of cervical screening outweigh potential risks,5 14 15 
persuasive messages raise ethical concerns to the extent 
that harms are possible.18 26 63 Persuasive messages may 
also contribute to widespread enthusiasm for cancer 
screening,64 65 discouraging people from reasoning about 
their screening choices.26 Moreover, while guidelines 
for screening communications tend to focus on health 
service providers,17–19 conflicting recommendations from 
different sources might create public confusion, negative 
beliefs about recommendations and scientific research, 
and potentially reduce screening intentions.66 67
Strengths of our analyses include their comprehen-
siveness and systematic examination of website content 
using an established checklist of information items,30 and 
recommendations from the literature for quantitative 
presentation formats. Additionally, our analyses included 
most of the websites that UK citizens may realistically 
access, as our strategy for website selection was based on 
the top results identified by the most commonly used 
Google search terms. Our approach could be used by 
researchers and practitioners to evaluate the content and 
format of websites about related topics (eg, other types 
of screening) in different countries. This would allow 
comparisons of websites for countries that have organ-
ised versus opportunistic screening. For example, website 
content may be more heterogeneous in countries such 
as the USA, which do not have organised screening. It 
would also be interesting to compare different platforms 
(eg, desktop websites vs mobile tailored versions), and to 
examine whether different design features (eg, informa-
tion position68) affect information readability, saliency or 
users’ information seeking behaviour .
Limitations of our study include that our analyses 
may not have covered all information that is poten-
tially relevant for screening decisions. For example, we 
did not assess whether websites discussed HPV, or the 
uncertainty associated with estimated benefits and risks. 
Communicating uncertainty can be challenging,69–71 
but is important for informed decision-making.16 17 41 
Conversely, it is possible that not all codes assessed are 
essential for informed screening decisions. We also did 
not directly examine whether users can make informed 
screening decisions based on the different websites. It is 
likely, however, that following guidelines and recommen-
dations from the literature will facilitate better under-
standing and more informed decisions. Explicit appeals 
to informed decision-making may also encourage users to 
evaluate the content, but of course do not guarantee that 
informed decisions will occur.
Future work should aim to identify essential infor-
mation items for informed decisions about screening, 
considering both experts’ and women’s views. As noted 
by Ghanouni et al,72 guidelines often do not provide 
detailed advice on which specific screening benefits, 
risks, or results should be discussed in communications. 
Moreover, experts may not fully agree on the relative 
importance of different information items, and women 
may have different information needs and preferences, 
including about whether and when to receive informa-
tion about further tests. Providing too much unfamiliar 
information initially may also overwhelm screening invi-
tees, and potentially distract them from key information 
necessary for decision-making.22 73 More research is also 
needed to identify how to best convey the individual 
significance of the population-level estimates included 
in screening communications, which may be hard for 
people to understand.74 Finally, future studies should 
also examine how screening decisions (eg, intentions to 
participate75) are affected by information about specific 
benefits and/or risks presented using different formats, 
building on the risk communication literature (eg,76). 
Such work would provide valuable insights to inform the 
design of evidence-based public communications about 
screening.
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